Tagged with Exclusive

Pharma The Executive Director of AmCham Singapore, former US Ambassador Judith Fergin, highlights why American companies are the largest source of FDI in the country and how Singapore’s enterprise-friendly environment has made it a hotbed for international investor interest. Can you please provide an overview of the chamber’s presence within Singapore…

Pharma Martin Naville, CEO of the Swiss-American Chamber of Commerce, discusses Swiss exports to the US, global competitiveness and innovation rankings, and why the Swiss-US relationship will only continue to grow stronger in the coming years. In 2015, the US was the most important destination for Swiss direct investment abroad, amounting…

Pharma Thilo Stadler speaks passionately about Grünenthal’s collaborative partnerships, company goals, and workforce engagement; revealing himself to be someone who truly believes in Grünenthal’s business. You currently hold the position of Regional General Manager South Europe and the Nordics and Managing Director of the Italian subsidiary. What were the main objectives…

Pharma The country manager of LEO Pharma Czech Republic and Slovakia explains how the recent acquisition of Astella’s dermatology portfolio will triple the revenue of the affiliate and how LEO always puts patients first Could you please introduce yourself and the cornerstones of your longstanding career in the pharmaceutical industry? The…

Healthcare In part two of a two-part interview (read part one here), Mikel Arriola of the IMSS discusses the strategic roadmap IMSS will follow under his tenure with regards to innovation access and chronic disease prevention, as well as his approach to the upcoming implementation of exchanges of services among the…

Healthcare In part one of a two-part interview (read part two here), Mikel Arriola, the recently appointed general director of IMSS (Mexican Social Security Institute), which provides health-related services to more than 70 million beneficiaries, reveals his fundamental priorities to both secure IMSS’ financial sustainability and improve the quality of services…

Pharma Merck Czech Republic’s MD reveals his plan to double Merck operations within the next five years and talks about the impact of the recent acquisition of Sigma Aldrich on the Czech Republic. You’ve assumed position as Managing Director Merck Czech Republic just over one year ago; what was the strategy…

Pharma The president of the Czech Academy of Sciences highlights the responsibility of leading scientists to consider the real life application of their academic results in addition to promoting the Czech sciences in world leading publications. Could you please briefly elaborate the history and background of the Czech Academy of Sciences?…

Pharma Rafael Suarez, general manager of Ferring in Mexico, explains how the Swiss biopharmaceutical company is adapting to the recent dynamics affecting both the Mexican public and private sectors. He outlines his approach to further consolidate the Mexican affiliate, increase Ferring’s clinical research investments and manufacturing presence in Mexico. When Pharmaceutical…

Pharma As President of Biopharma Activities for Merck in France, Pierre-Henry Longeray reveals how France is the third ranked affiliate after the US and Germany for the Group; how the French culture of innovation is one of the main drivers of the business; and how Merck is shifting from a pharmaceutical…

Pharma Dr. Teresa Corona Vázquez, the general director of one of the leading neuroscience institutions in Latin America, details their most important research partnerships and achievements, notably with regards to neurodegenerative diseases, and her expectations of fostering a heightened research-based relationship with the pharmaceutical industry. What have been some of the…

Pharma Axel B. Müller, managing director of Intergenerika, the Swiss generics association, reveals the penetration rate of generics in Switzerland; why generics are a safe, and smarter choice, manufactured to modern standards with affordable prices; and the threat of government forcing generic companies to benchmark their prices to nine European countries…